About Small Cell Lung Cancer
Cancer occurs when, after cell transformation, normal cells grow and multiply without control. Lung cancer is a common cause of mortality and morbidity in developed and developing countries. Smoking is considered to be the major cause of small cell lung cancer, though it also occurs in non-smokers. Lung cancer can be categorized into two types: non-small cell lung cancer and small cell lung cancer. Small cell lung cancer constitutes roughly 10-15 percent of all diagnosed cases of lung cancer. Small cell lung cancer is categorized into two types: small cell carcinoma and combined small cell carcinoma. It can be further classified into two stages: limited-stage small cell lung cancer and extensive-stage small cell lung cancer. Small cell lung cancer is caused by smoking tobacco, or second hand smoking, or on exposure to asbestos, chromium, arsenic, nickel, soot, or radon. The common symptoms associated with lung cancer are chest pain, incurable cough, blood in sputum, fatigue, loss of appetite, unintentional weight loss, shortness of breath, and wheezing. Small cell lung cancer has a poor prognosis and gets diagnosed only at the late stage of disease progression, and hence, has a high mortality rate. There are no therapies available to cure small cell lung cancer in the market.
TechNavio's analysts forecast the Global Small Cell Lung Cancer Therapeutics market to grow at a CAGR of 3.60 percent over the period 2014-2019.
Covered in this Report
TechNavio's report, Global Small Cell Lung Cancer Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Small Cell Lung Cancer Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• APAC
• EMEA
Key Vendors
• Bristol-Myers Squibb
• GlaxoSmithKline
• Menarini
• Sanofi
• ZIOPHARM Oncology
Other Prominent Vendors
• Alchemia
• Amgen
• Apotex
• BioMarin Pharmaceutical
• CellAct Pharma
• Cerulean Pharma
• Cipla
• Cornerstone Pharmaceuticals
• Curis
• CytRx
• Eli Lilly
• Exelixis
• Fresenius Kabi
• Genentech
• Hikma Pharmaceuticals
• Hospira
• Intas Pharmaceuticals
• Karyopharm Therapeutics
• Kyowa Hakko Kirin
• Ligand Pharmaceuticals
• Lundbeck
• MabVax Therapeutics Holdings
• Medac Pharma
• MEI Pharma
• Merck
• MolMed
• Mologen
• Mylan
• Nektar Therapeutics
• Neotropix
• Novartis
• Novogen
• OncoMed Pharmaceuticals
• Ono Pharmaceutical
• PharmaMar
• Polaris Group
• Sagent Pharmaceuticals
• Shanghai Jinhe Bio-Technology
• Spectrum Pharmaceuticals
• STADA Arzneimittel
• Stem CentRx
• Sun Pharmaceuticals Industries
• Takeda Pharmaceutical
• Teva Pharmaceutical
• Zydus Cadila Healthcare
Market Driver
• High Unmet Need
• For a full, detailed list, view our report
Market Challenge
• High Cost of Treatment
• For a full, detailed list, view our report
Market Trend
• Strategic Alliances
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Disease Overview
05.1 Understanding the Disease
05.2 Classification
05.2.1 Small Cell Carcinoma
05.2.2 Combined Small Cell Carcinoma
05.3 Diagnosis
05.3.1 Physical Examination
05.3.2 Laboratory Tests
05.3.3 Chest X-ray
05.3.4 Sputum Cytology
05.3.5 CT Scan
05.3.6 Biopsy
05.3.7 Light and Electron Microscopy
05.3.8 Immunohistochemistry
05.4 Rate of Incidence and Prevalence
05.5 Staging
05.6 Management
05.7 Economic Burden
06. Introduction
07. Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Top Predictions
07.4 Five Forces Analysis
08 Pipeline Analysis
08.1 Key Information on the Pipeline Candidates
08.1.1 Palifosfamide (ZIO-201)
08.1.2 Ipilimumab+Etoposide+Cisplatin/Carboplatin
08.1.3 Ipilimumab
08.1.4 Enoxaparin Sodium
08.1.5 BAY1000394 (Roniciclib)
08.1.6 Nivolumab (ONO-4538/ BMS-936558)
08.1.7 BMS-986012
08.1.8 LY2940680
08.1.9 Sabarubicin (MEN 10755)
08.1.10 CAP7.1
08.1.11 SC16LD6.5
08.1.12 BIW-8962
08.1.13 AMG 479 (Ganitumab)
08.1.14 LY2510924
08.1.15 Trisenox
08.1.16 MGN1703
08.1.17 Tarextumab (OMP-59R5)
08.1.18 BMN 673 (Talazoparib Tosylate)
08.1.19 NGR-hTNF
08.1.20 CPI-613
08.1.21 Alisertib (MLN8237)
08.1.22 Vismodegib (GDC-0449, Erivedge)
08.1.23 Cabozantinib (XL184 or Cometriq)
08.1.24 Selinexor (KPT-330)
08.1.25 ADI-PEG 20 (Pegargiminase)
08.1.26 Etirinotecan Pegol (NKTR-102)
08.1.27 CRLX101 (IT-101 or Cyclodextrin-based Polymer-camptothecin IT-101)
08.1.28 NTX-010
08.1.29 Aldoxorubicin
08.1.30 HA-Irinotecan
08.1.31 Carfilzomib
08.1.32 Small Cell Lung Cancer Vaccine
08.1.33 GSK2879552
08.1.34 NV-344 (ME-344)
08.1.35 BMS-833923 (XL139)
08.1.36 PM01183 (Lurbinectedin)
08.1.37 LDE225 (Erismodegib or Sonidegib)
08.1.38 Belinostat
08.2 Timeline for Major Products under Development
08.2.1 Palifosfamide (ZIO-201)
08.2.2 Sabarubicin (MEN 10755)
09. Market Segmentation by Therapeutic Class of Drugs
09.1 Alkylating Agents
09.2 Antimetabolites
09.3 Microtubule Inhibitors
09.4 Cytotoxic Antibiotics
09.5 Topoisomerase Inhibitors
09.6 Others
10 Market Segmentation by Route of Administration
10.1 Oral
10.2 Parenteral
11 Market Segmentation by Dosage Form
11.1 Solid
11.2 Liquid
12 Geographical Segmentation
12.1 Small Cell Lung Cancer Market in Americas
12.1.1 Market Size and Forecast
12.2 Small Cell Lung Cancer Market in EMEA Region
12.2.1 Market Size and Forecast
12.3 Small Cell Lung Cancer Market in APAC Region
12.3.1 Market Size and Forecast
13 Buying Criteria
14 Market Growth Drivers
15 Drivers and their Impact
16 Market Challenges
17 Impact of Drivers and Challenges
18 Market Trends
19 Trends and their Impact
20 Vendor Landscape
20.1 Competitive Scenario
20.1.1 Key News
20.1.2 Mergers and Acquisitions
20.2 Market Share Analysis 2014
20.2.1 Bristol-Myers Squibb
20.2.2 GlaxoSmithKline
20.2.3 Menarini
20.2.4 Sanofi
20.2.5 ZIOPHARM Oncology
20.3 Other Prominent Vendors
21 Key Vendor Analysis
21.1 Bristol-Myers Squibb
21.1.1 Key Facts
21.1.2 Business Overview
21.1.3 Key Product Offerings
21.1.4 Revenue by Geography
21.1.5 Business Strategy
21.1.6 Key Information
21.1.7 SWOT Analysis
21.2 GlaxoSmithKline
21.2.1 Key Facts
21.2.2 Business Overview
21.2.3 Business Segmentation
21.2.4 Business Segmentation by Revenue 2012 and 2013
21.2.5 Sales by Geography
21.2.6 Pipeline Products
21.2.7 Business Strategy
21.2.8 Key Information
21.2.9 SWOT Analysis
21.3 Menarini
21.3.1 Key Facts
21.3.2 Business Overview
21.3.3 Key Pipeline Products
21.3.4 Recent Developments
21.3.5 SWOT Analysis
21.4 Sanofi
21.4.1 Key Facts
21.4.2 Business Description
21.4.3 Business Segmentation
21.4.4 Revenue by Business Segmentation
21.4.5 Revenue Comparison 2012 and 2013
21.4.6 Sales by Geography
21.4.7 Business Strategy
21.4.8 Key Developments
21.4.9 SWOT Analysis
21.5 ZIOPHARM Oncology
21.5.1 Key Facts
21.5.2 Business Overview
21.5.3 Recent Developments
21.5.4 SWOT Analysis
22 Other Reports in this Series
List of Exhibits:
Exhibit 1: Market Research Methodology
Exhibit 2: Classification of Lung Cancer
Exhibit 3: Techniques for Diagnosing Small Cell Lung Cancer
Exhibit 4: Incidence of Lung Cancer in WHO Regions
Exhibit 5: Staging of Small Cell Lung Cancer
Exhibit 6: Small Cell Lung Cancer by Stage
Exhibit 7: Five-year Survival Rate of Small Cell Lung Cancer Patients
Exhibit 8: Stepwise Diagrammatic Representation of Management of Small Cell Lung Cancer (According to ESMO Guidelines)
Exhibit 9: Global Small Cell Lung Cancer Therapeutics Market 2014-2019 (US$ million)
Exhibit 10: Top Predictions in Global Small Cell Lung Cancer Therapeutics Market
Exhibit 11: Pipeline Portfolio of Small Cell Lung Cancer Drugs
Exhibit 12: Timeline of Palifosfamide (ZIO-201)
Exhibit 13: Timeline of Sabarubicin (MEN 10755)
Exhibit 14: Global Small Cell Lung Cancer Therapeutics Market by Therapeutic Class of Drugs
Exhibit 15: Segmentation of Global Small Cell Lung Cancer Therapeutics Market by Route of Administration
Exhibit 16: Segmentation of Global Small Cell Lung Cancer Therapeutics Market by Route of Administration 2014
Exhibit 17: Segmentation of Global Small Cell Lung Cancer Therapeutics Market by Dosage Forms
Exhibit 18: Segmentation of Global Small Cell Lung Cancer Therapeutics Market by Dosage Forms 2014
Exhibit 19: Segmentation of Global Small Cell Lung Cancer Therapeutics Market by Geography 2014
Exhibit 20: Segmentation of Global Small Cell Lung Cancer Therapeutics Market by Geography 2019
Exhibit 21: Small Cell Lung Cancer Therapeutics Market in Americas 2014-2019 (US$ million)
Exhibit 22: Small Cell Lung Cancer Therapeutics Market in EMEA Region 2014-2019 (US$ million)
Exhibit 23: Small Cell Lung Cancer Therapeutics Market in APAC Region 2014-2019 (US$ million)
Exhibit 24: Bristol-Myers Squibb Co.: Key Product Offerings (Based on Therapeutic Areas)
Exhibit 25: Bristol-Myers Squibb Co.: Revenue by Geographical Segmentation 2013
Exhibit 26: GlaxoSmithKline: Business Segmentation 2013
Exhibit 27: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 28: GlaxoSmithKline: Sales by Geography 2013
Exhibit 29: GlaxoSmithKline: Pipeline Products 2013
Exhibit 30: Menarini: Key Pipeline Products
Exhibit 31: Sanofi SA: Business Segmentation
Exhibit 32: Sanofi SA: Revenue by Business Segmentation 2013
Exhibit 33: Sanofi SA: Revenue by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 34: Sanofi SA: Sales Revenue by Geographical Segmentation 2013
